Ali Mokdad, PhD, reported in JAMA that “cancer mortality rates in the United States dropped from 240.2 to 192.0 per 100,000 population between 1980 and 2014.”1 However, according to the [ Read More ]
Best Practices in lung cancer – November 2017 Vol 8
In Recognition of Lung Cancer Awareness Month
The principles of navigation began in the discipline of breast cancer. After observing the tremendous success of removing barriers to care as an effective method to improve clinical outcome and patient satisfaction, navigation tactics have been incorporated into many oncology disciplines. In this Special Edition, we direct our attention to lung cancer and the positive impact navigators have had in this disease state.
Lung cancer is a field in which great strides have been made over the past decade. From smoking cessation programs to the introduction of immunotherapy to the development and implementation of lung nodule screening, patients living with lung cancer have more treatment options and lifestyle-enhancing services available to them than ever before.
In this issue, we present an interview with Wendy Brooks, RN, ONN-CG(T), a thoracic nurse navigator at the HCA Midwest Research Medical Center, about her typical, or not so typical, day as a navigator. We are pleased to present an article by Amy M. Norton, RN, MSN, ONN-CG(T), and colleagues entitled “Lung Cancer. Now What? Plans and How We ‘Navigate’ Them.” We also bring you news in lung cancer from the European Society for Medical Oncology 2017 Congress.
It is our hope that this issue is a valuable resource to the nurse and patient navigators who work tirelessly to help their patients living with lung cancer. Thank you for all you do for your patients and for your valued and loyal readership.
Lillie D. Shockney, RN, BS, MAS, ONN-CG
Editor-in-Chief, JONS; Program Director, AONN+
University Distinguished Service Professor of Breast Cancer; Administrative Director, the Johns Hopkins Breast Center; Director, Cancer Survivorship Programs at the Sidney Kimmel Cancer Center at Johns Hopkins; Professor, JHU School of Medicine, Depts of Surgery and Oncology; Cofounder, Johns Hopkins Medicine Managing Cancer at Work.
Durvalumab, a PD-L1 inhibitor, improved progression-free survival (PFS) by 11.2 months compared with placebo in patients with locally advanced, unresectable stage III non–small cell lung cancer (NSCLC) that did not [ Read More ]